Condition: Advanced Solid Tumor · TNBC - Triple-Negative Breast Cancer · Gastric Cancer · Sponsor: SillaJen, Inc.
This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and tolerability of increasing doses of BAL0891 in patients with advanced solid tumors or relapsed or refractory acute myeloid leukemia. An adaptive model-based design will be used to guide the dose escalation. Subject assignment to Substudy 1, 2, 3 and 4 will be finalized following approval from the investigator and sponsor. The dose-expansion stage will be conducted with the RP2D to further evaluate the preliminary anti-tumor activity, safety, and tolerability in metastatic TNBC and GC.
This description comes directly from the study's public registry record.
SillaJen Inc. · 02-368-2600 · patient_inquiry@sillajen.com
Always discuss trial participation with your own doctor first.
| Yale New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
| University of Miami Health System | Coral Gables, Florida, United States | Recruiting |
| Winship Cancer Institute / Emory University | Atlanta, Georgia, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| New York Medicine-New York-Presbyterian Hospital | New York, New York, United States | Recruiting |
| Montefiore Medical Center - Montefiore Hospital | New York, New York, United States | Recruiting |
| Montefiore Medical Center | The Bronx, New York, United States | Recruiting |
| OHSU Knight Cancer Institute | Portland, Oregon, United States | Completed |
| Mary Crowley Cancer Research | Dallas, Texas, United States | Completed |
| Baylor University Medical Center | Dallas, Texas, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| The Catholic University of Korea, Seoul St. Mary's Hospital | Seoul, South Korea | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05768932